SEC Form 4	
------------	--

П

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPRC	VAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person*		2. Issuer Name <b>and</b> Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Pomerantz Roger		r	X Director 10% Owner					
			X Officer (give title Other (specify					
(Last) (First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	below) below)					
C/O SERES THERAPEUTIC	S, INC.	07/01/2016	President and CEO					
200 SIDNEY STREET								
		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable					
(Street)			Line)					
CAMBRIDGE MA	02139		X Form filed by One Reporting Person					
· · · · · · · · · · · · · · · · · · ·			Form filed by More than One Reporting Person					
(City) (State)	(Zip)							

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)	
Common Stock	07/01/2016		М		56,789	A	\$0.71	240,481	D		
Common Stock	07/01/2016		S <sup>(1)</sup>		4,832	D	<b>\$29.12</b> <sup>(2)</sup>	235,649	D		
Common Stock	07/01/2016		S <sup>(1)</sup>		41,957	D	\$29.84 <sup>(3)</sup>	193,692	D		
Common Stock	07/01/2016		S <sup>(1)</sup>		10,000	D	\$30	183,692	D		

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$0.71	07/01/2016		М			56,789	(4)	08/07/2024	Common Stock	56,789	\$0.00	1,160,497	D	

### Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on February 26, 2016.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from \$28.61 to \$29.605. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from \$29,635 to \$30.005. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The option vested as to 25% of the shares subject to the option on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter.

## **Remarks:**

## /s/ Eric Shaff, Attorney-in-fact 07/05/2016

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.